EUVIMEDEUVIMED entdecken
Crossref

Identification of RdRp-NiRAN/JAK1 Dual-Target Drugs for COVID-19 Treatment

Huixuan Zhao, Xiaoyu Chang, Lei Sun iD, Ertong Li, Depeng Zhang, Wentao Qi, Jijie Chai, Xueping Hu iD, Weiqiao Deng iD

The Journal of Physical Chemistry B · 2024

DOI: 10.1021/acs.jpcb.4c06123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Physical Chemistry B, 2024. Verfasst von Huixuan Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Frontier Chemistry, School of Chemistry and Chemical Engineering, Shandong University, Qingdao 266237, China. Hauptthemen laut MEDLINE: Janus Kinase 1, COVID-19 Drug Treatment, Antiviral Agents, Molecular Docking Simulation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Taishan Scholar Foundation of Shandong Province, Shandong University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inhibition of virus replication and inflammatory response is important for the treatment of severe COVID-19 patients. RNA-dependent RNA polymerase (RdRp) is indispensable for SARS-CoV-2 replication, and Janus kinase (JAK) 1 inhibitors exert immunosuppressive effects. RdRp/JAK1 dual-target drugs are expected to ameliorate the severity of the COVID-19 disease. The N-terminal nidovirus RdRp-associated nucleotidyltransferase (NiRAN) domain of RdRp is a pseudokinase, and it has structural similarities with JAK1. Herein, we evaluated the inhibitory effects of triphosphate forms of 31 nucleoside drugs in the DrugBank database on the NiRAN domain and JAK1 through a combination of theoretical and experimental methods. By analyzing the three properties of 31 nucleoside drugs (total hydrophobic surface area, number of hydrophobic atoms, and molecular weight), these drugs met the application rule of our developed molecular docking with conformer-dependent charges (MDCC). Based on the MDCC method combined with molecular dynamics simulations, Azvudine and Citicoline among these 31 drugs showed stronger predicted binding affinities with the NiRAN domain as well as JAK1 compared to the reference drug Remdesivir. Further experimental verification, including a thermal shift assay and homogeneous time-resolved fluorescence assay, demonstrated that Azvudine was an RdRp-NiRAN/JAK1 dual-target drug. This work provided a previously unexplored mechanism of Azvudine for COVID-19 treatment and proposed a design concept for RdRp-NiRAN/JAK1 dual-target nucleoside drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase 1COVID-19 Drug TreatmentAntiviral AgentsMolecular Docking SimulationMolecular Dynamics SimulationSARS-CoV-2HumansRNA-Dependent RNA Polymerase

Substanzen

Janus Kinase 1Antiviral AgentsJAK1 protein, humanRNA-Dependent RNA Polymerase

Autor:innen und Institutionen

  • Institute of Frontier Chemistry, School of Chemistry and Chemical Engineering, Shandong University, Qingdao 266237, China.
  • School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
  • Chemical Engineering and Resource Utilization, College of Chemistry, Northeast Forestry University, Harbin 150040, China.
  • Normal School, Shenyang University, Shenyang 110044, China.
  • School of Life Sciences, Tsinghua University, Beijing 100084, China.

ORCID-Profile: Lei Sun, Xueping Hu, Weiqiao Deng

Förderung

  • National Key Research and Development Program of China
  • Taishan Scholar Foundation of Shandong Province
  • Shandong University
  • National Natural Science Foundation of China
  • Youth Innovation Team Project for Talent Introduction and Cultivation in Universities of Shandong Province

Zitieren

APA

Zhao, H., Chang, X., Sun, L., Li, E., Zhang, D., Qi, W., Chai, J., Hu, X., & Deng, W. (2024). Identification of RdRp-NiRAN/JAK1 Dual-Target Drugs for COVID-19 Treatment. The Journal of Physical Chemistry B. https://doi.org/10.1021/acs.jpcb.4c06123

Vancouver

Zhao H, Chang X, Sun L, Li E, Zhang D, Qi W, et al. Identification of RdRp-NiRAN/JAK1 Dual-Target Drugs for COVID-19 Treatment. The Journal of Physical Chemistry B. 2024. doi:10.1021/acs.jpcb.4c06123

BibTeX
@article{Zhao2024,
  author = {Zhao, Huixuan and Chang, Xiaoyu and Sun, Lei and Li, Ertong and Zhang, Depeng and Qi, Wentao and Chai, Jijie and Hu, Xueping and Deng, Weiqiao},
  title = {Identification of RdRp-NiRAN/JAK1 Dual-Target Drugs for COVID-19 Treatment},
  journal = {The Journal of Physical Chemistry B},
  year = {2024},
  doi = {10.1021/acs.jpcb.4c06123}
}
Kostenlos starten →